Relay Therapeutics' (RLAY) zovegalisib receives FDA Breakthrough Therapy designation for treating PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 inhibitor treatment.
Oppenheimer upgrades Relay Therapeutics to Outperform, citing potential upside from competitor trial risks and upcoming VIKTORIA-1 results.
Wells Fargo upgrades Relay Therapeutics and Zymeworks, raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities.
